סופרפאקט דפו 3 חודשים
sanofi - aventis israel ltd - buserelin acetate - קנים להשתלה - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).
זולדקס אל.אי.
astrazeneca (israel) ltd - goserelin as acetate - שתל להזרקה - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.
זולדקס
astrazeneca (israel) ltd - goserelin as acetate - שתל - goserelin as acetate 3.6 mg/unit - goserelin - goserelin - treatment of prostate cancer suitable for hormonal manipulation. breast cancer in pre-menopausal women suitable for hormone manipulation.endometriosis. assisted reproduction: pituitary down regulation in preparion for superovulation. endometrial thinning: zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. uterine fibroids: for reduction of fibroid size prior to surgery.
powerline
a.m.i. technologies, ltd. - מומחה - ptca cathethers and delivery system
סופרפקט דפו חודשיים
sanofi - aventis israel ltd - buserelin acetate 6.6 mg - rods for implant - buserelin - treatment of advanced hormone - dependent prostatic carcinoma.
סופרפקט תרסיס לאף
sanofi - aventis israel ltd - buserelin as acetate 0.1 mg/actuations - solution - buserelin - treatment of advanced hormone dependent prostatic carcinoma. endometriosis. use in ivf. precocious puberty. leyomyoma uteri.
רספטל וטרינרי
intervet ( israel) ltd - buserelin as acetate - תמיסה להזרקה - buserelin as acetate 0.004 mg/ml
ביקאלוטמיד אינובמד 150 מג
inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable
טלזנה 0.25 מג
pfizer pharmaceuticals israel ltd - talazoparib as tosylate - קפסולה קשיחה - talazoparib as tosylate 0.25 mg - talazoparib
טלזנה 1 מג
pfizer pharmaceuticals israel ltd - talazoparib as tosylate - קפסולה קשיחה - talazoparib as tosylate 1 mg - talazoparib